p53-MDM2-IN-5 (compound 5a), a robust p53-MDM2 inhibitor, effectively induces apoptosis, autophagy, and DNA damage. It also causes cell cycle arrest at the S and G2/M phases and demonstrates anti-tumor activity.

p53-MDM2-IN-5 (compound 5a) (1-5 µM; 24 h) induces apoptosis in A549 cells, causing cell cycle arrest at the S and G2/M phases [1]. Additionally, at concentrations of 1 and 5 µM over 24 hours, p53-MDM2-IN-5 prompts autophagy by reducing the expression of SQSTM1/p62 [1].

p53-MDM2-IN-5, administered intravenously at a dosage of 6 μmol/kg every three days for 21 days, demonstrated antitumor activity in the A549 xenograft nude mouse model [1]. Animal Model: 6–8-week-old female nude mice (A549 xenograft) [1]. Result: Inhibition of tumor growth with minimal toxicity.